Ditan
| Ditan | |
|---|---|
| Drug class | |
 Lasmiditan | |
| Class identifiers | |
| Use | Migraine |
| Biological target | 5-HT1F receptor |
| Legal status | |
| In Wikidata | |
Ditans are a class of
, was approved by the FDA in 2019.Ditans selectively bind to the
Raynaud's phenomenon or after a myocardial infarction.[2] A 1998 review has found such side effects to rarely occur in most patients taking triptans.[3][4]
One clinical trial showed that 200 mg lasmiditan provided pain freedom by 2 hours in 32% of individuals with migraine attacks of moderate or severe intensity, and 100 mg lasmiditan did so in 28%, compared with 15% after a placebo.[5] Subsequently, these results were confirmed in another trial.[6]
References
- S2CID 221753230.
- ^ "Molecule of the Month July 2010: Lasmiditan hydrochloride". Prous Science. Retrieved 2011-08-03.
- S2CID 30125923.
- ^ Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M. Arzneimittelwirkungen. Wissenschaftliche Verlagsgesellschaft.
- PMID 30446595.
- PMID 31132795.